5avi - Revision history

OCA at 15:49, 8 November 2023

2023-11-08T15:49:06Z

←Older revision		Revision as of 15:49, 8 November 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AVI FirstGlance]. <br>		<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AVI FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.7Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [https://pdbe.org/5avi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [https://www.ebi.ac.uk/pdbsum/5avi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5avi ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [https://pdbe.org/5avi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [https://www.ebi.ac.uk/pdbsum/5avi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5avi ProSAT]</span></td></tr>
	</table>		</table>

OCA at 06:27, 31 May 2023

2023-05-31T06:27:13Z

←Older revision		Revision as of 06:27, 31 May 2023
Line 3:		Line 3:
	<StructureSection load='5avi' size='340' side='right'caption='[[5avi]], [[Resolution\|resolution]] 2.70Å' scene=''>		<StructureSection load='5avi' size='340' side='right'caption='[[5avi]], [[Resolution\|resolution]] 2.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5AVI FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5AVI FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene~~></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">NR1H3, LXRA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [https://pdbe.org/5avi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [https://www.ebi.ac.uk/pdbsum/5avi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5avi ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histone_acetyltransferase Histone acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.48 2.3.1.48] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [~~http~~://pdbe.org/5avi PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5avi PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5avi ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Note=A chromosomal aberration involving NCOA1 is a cause of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3 generates the NCOA1-PAX3 oncogene consisting of the N-terminus part of PAX3 and the C-terminus part of NCOA1. The fusion protein acts as a transcriptional activator. Rhabdomyosarcoma is the most common soft tissue carcinoma in childhood, representing 5-8% of all malignancies in children.	+	[https://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN] Note=A chromosomal aberration involving NCOA1 is a cause of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3 generates the NCOA1-PAX3 oncogene consisting of the N-terminus part of PAX3 and the C-terminus part of NCOA1. The fusion protein acts as a transcriptional activator. Rhabdomyosarcoma is the most common soft tissue carcinoma in childhood, representing 5-8% of all malignancies in children.
	== Function ==		== Function ==
-	[[http://www.uniprot.org/uniprot/NR1H3_HUMAN NR1H3_HUMAN]] Orphan receptor. Interaction with RXR shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity). [[http://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3.<ref>PMID:9427757</ref> <ref>PMID:7481822</ref> <ref>PMID:9223431</ref> <ref>PMID:9296499</ref> <ref>PMID:9223281</ref> <ref>PMID:10449719</ref> <ref>PMID:12954634</ref>	+	[https://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN] Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3.<ref>PMID:9427757</ref> <ref>PMID:7481822</ref> <ref>PMID:9223431</ref> <ref>PMID:9296499</ref> <ref>PMID:9223281</ref> <ref>PMID:10449719</ref> <ref>PMID:12954634</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 29:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Histone acetyltransferase]]~~	+	[[Category: Homo sapiens]]
-	~~[[Category: Human~~]]	+
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Hanzawa, H]]	+	[[Category: Hanzawa H]]
-	[[Category: Matsui, Y]]	+	[[Category: Matsui Y]]
-	[[Category: Tamaki, K]]	+	[[Category: Tamaki K]]
-	~~[[Category: Agonist]]~~	+
-	~~[[Category: Complex]]~~	+
-	~~[[Category: Transcription~~]]	+

OCA at 07:37, 3 July 2019

2019-07-03T07:37:58Z

←Older revision		Revision as of 07:37, 3 July 2019
Line 1:		Line 1:
		+
	==Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4==		==Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4==
-	<StructureSection load='5avi' size='340' side='right' caption='[[5avi]], [[Resolution\|resolution]] 2.70Å' scene=''>	+	<StructureSection load='5avi' size='340' side='right'caption='[[5avi]], [[Resolution\|resolution]] 2.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AVI FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AVI FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">NR1H3, LXRA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histone_acetyltransferase Histone acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.48 2.3.1.48] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histone_acetyltransferase Histone acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.48 2.3.1.48] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [http://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [http://www.ebi.ac.uk/pdbsum/5avi PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [http://pdbe.org/5avi PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [http://www.ebi.ac.uk/pdbsum/5avi PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5avi ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 19:		Line 21:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 5avi" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Liver X receptor\|Liver X receptor]]
	== References ==		== References ==
	<references/>		<references/>
Line 24:		Line 30:
	</StructureSection>		</StructureSection>
	[[Category: Histone acetyltransferase]]		[[Category: Histone acetyltransferase]]
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Hanzawa, H]]		[[Category: Hanzawa, H]]
	[[Category: Matsui, Y]]		[[Category: Matsui, Y]]

OCA at 13:25, 26 August 2015

2015-08-26T13:25:53Z

←Older revision		Revision as of 13:25, 26 August 2015
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4==
		+	<StructureSection load='5avi' size='340' side='right' caption='[[5avi]], [[Resolution\|resolution]] 2.70Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5avi]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AVI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AVI FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4KM:TERT-BUTYL+2-[[4-[ETHANOYL(METHYL)AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE'>4KM</scene></td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histone_acetyltransferase Histone acetyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.3.1.48 2.3.1.48] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5avi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5avi OCA], [http://www.rcsb.org/pdb/explore.do?structureId=5avi RCSB], [http://www.ebi.ac.uk/pdbsum/5avi PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Note=A chromosomal aberration involving NCOA1 is a cause of rhabdomyosarcoma. Translocation t(2;2)(q35;p23) with PAX3 generates the NCOA1-PAX3 oncogene consisting of the N-terminus part of PAX3 and the C-terminus part of NCOA1. The fusion protein acts as a transcriptional activator. Rhabdomyosarcoma is the most common soft tissue carcinoma in childhood, representing 5-8% of all malignancies in children.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/NR1H3_HUMAN NR1H3_HUMAN]] Orphan receptor. Interaction with RXR shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity). [[http://www.uniprot.org/uniprot/NCOA1_HUMAN NCOA1_HUMAN]] Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3.<ref>PMID:9427757</ref> <ref>PMID:7481822</ref> <ref>PMID:9223431</ref> <ref>PMID:9296499</ref> <ref>PMID:9223281</ref> <ref>PMID:10449719</ref> <ref>PMID:12954634</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	To obtain potent liver X receptor (LXR) agonists, a structure-activity relationship study was performed on a series of tert-butyl benzoate analogs. As the crystal structure analysis suggested applicable interactions between the LXR ligand-binding domain and the ligands, two key functional groups were introduced. The introduction of the hydroxyl group on the C6-position of the benzoate part enhanced the agonistic activity in a cell-based assay, and the carboxyl group in terminal improved the pharmacokinetic profile in mice, respectively. The obtained compound 32b increased blood ABCA1 mRNA expression without plasma TG elevation in both mice and cynomolgus monkeys.

-	~~The entry 5avi is ON HOLD until Paper Publication~~	+	Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.,Matsui Y, Yamaguchi T, Yamazaki T, Yoshida M, Arai M, Terasaka N, Honzumi S, Wakabayashi K, Hayashi S, Nakai D, Hanzawa H, Tamaki K Bioorg Med Chem Lett. 2015 Sep 15;25(18):3914-20. doi:, 10.1016/j.bmcl.2015.07.047. Epub 2015 Jul 23. PMID:26238323<ref>PMID:26238323</ref>

-	~~Authors: Matsui~~, Y.~~, Hanzawa, H~~.~~, Tamaki, K~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description~~: ~~Crystal structure of LXRalpha in complex with tert-butyl benzoate analog~~	+	== References ==
-	[[Category: ~~Unreleased Structures~~]]	+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Histone acetyltransferase]]
		+	[[Category: Hanzawa, H]]
		+	[[Category: Matsui, Y]]
	[[Category: Tamaki, K]]		[[Category: Tamaki, K]]
-	[[Category: ~~Matsui, Y~~]]	+	[[Category: Agonist]]
-	[[Category: ~~Hanzawa, H~~]]	+	[[Category: Complex]]
		+	[[Category: Transcription]]

OCA at 10:38, 1 July 2015

2015-07-01T10:38:31Z

←Older revision		Revision as of 10:38, 1 July 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5avi is ON HOLD	+	The entry 5avi is ON HOLD until Paper Publication

	Authors: Matsui, Y., Hanzawa, H., Tamaki, K.		Authors: Matsui, Y., Hanzawa, H., Tamaki, K.

OCA: Protected "5avi" [edit=sysop:move=sysop]

2015-06-24T11:28:38Z

Protected "5avi" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:28, 24 June 2015

OCA: New page: '''Unreleased structure''' The entry 5avi is ON HOLD Authors: Matsui, Y., Hanzawa, H., Tamaki, K. Description: Crystal structure of LXRalpha in complex with tert-butyl benzoate analog ...

2015-06-24T11:28:37Z

New page: '''Unreleased structure''' The entry 5avi is ON HOLD Authors: Matsui, Y., Hanzawa, H., Tamaki, K. Description: Crystal structure of LXRalpha in complex with tert-butyl benzoate analog ...

New page

'''Unreleased structure'''

The entry 5avi is ON HOLD

Authors: Matsui, Y., Hanzawa, H., Tamaki, K.

Description: Crystal structure of LXRalpha in complex with tert-butyl benzoate analog
[[Category: Unreleased Structures]]
[[Category: Tamaki, K]]
[[Category: Matsui, Y]]
[[Category: Hanzawa, H]]